

Brief Communication:

Combating COVID-19: Lessons learnt particularly among developing countries and the implications

Brian Godman

Keywords: Bangladesh, COVID-19, evidence-based medicine, misinformation, stigma, unintended consequences.

*Bangladesh Journal of Medical Science, Special Issue on Covid19, 2020. Page : S 103-S 108
DOI: <https://doi.org/10.3329/bjms.v19i0.48413>*

We believe COVID-19 was first identified in Wuhan, China, in December 2019¹⁻³. By 19 July 2020 there were already 14.349 million cases and over 603,000 deaths worldwide giving a case fatality ratio among confirmed cases of 4.21%⁴. This includes Bangladesh with 204,525 confirmed cases by 19 July and 2618 deaths; however, recognising appreciable underreporting³⁻⁵. Since COVID-19 is principally spread through droplet infection and physical contact⁶, with an appreciable number of patients asymptomatic and currently no vaccine, current prevention strategies have centred on active testing, lockdown, closure of borders coupled with quarantining, sanitisation and social distancing⁶⁻¹². However, the rate of adoption of preventative measures has varied considerably across countries, exacerbated by lack of testing facilities, clean water/ sanitisation and economic concerns, affecting prevalence and mortality rates^{5,13,14}. Vietnam is an example of a developing country that rapidly introduced a range of measures under the banner 'Fighting the epidemic is like fighting against the enemy', which combined with other factors have resulted in only 383 reported cases up to 19 July and no deaths^{4,15-17}. Rapid initiatives among a number of African countries including Botswana and Namibia have also limited prevalence and mortality rates in these countries¹³. This is despite concerns that patients of Black Afro-

Caribbean and South Asian origin with COVID-19 in the United Kingdom appear at appreciably increased risk of dying from COVID-19 versus those of white ethnicity¹⁸⁻²². The lack of intensive care beds and ventilatory support has also been a concern among developing countries during the pandemic potentially adversely affecting mortality rates^{5,13}; however, we are seeing shortages of ventilators being addressed through local innovations¹³.

A number of medicines have been proposed for managing patients with COVID-19^{23,24}. However, to date, there appears to be no cure although dexamethasone and remdesivir are showing promise in well constructed studies^{5,25-27}. Initially, there was considerable hype surrounding the use of chloroquine and hydroxychloroquine with or without antibiotics such as azithromycin^{5,28-30} despite concerns with the lack of control arms in the initial studies³¹. The hype resulted in appreciable increases in the utilisation and prices of antimalarials as well as suicides across a number of countries, enhanced by endorsement from Governments and Medical Societies^{5,32-35}. However, more recent studies, including randomised clinical trials, failed to show any benefit alongside potential harm³⁶⁻⁴⁰. As a result, the World Health Organisation (WHO) and the National Institute of Health in the US have stopped the hydroxychloroquine arm in their studies, with Governments, Societies and Agencies

Correspondence to: Brian Godman - Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, United Kingdom; Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden; School of Pharmacy, Sefako Makgatho Health Sciences University, Ga-Rankuwa, Pretoria, South Africa and School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia. Email: Brian.Godman@strath.ac.uk. ORCID ID: <http://orcid.org/0000-0001-6539-6972>

now also advising caution⁴¹⁻⁴⁵. Hydroxychloroquine is still endorsed though in India for prophylaxis following the study of Chatterjee *et al.* (2020) despite concerns^{46,47}.

Recommendations of unproven or ineffective medicines are a concern in countries where there are high levels of co-payment, and where the costs of providing treatment for family members can have catastrophic consequences as seen for instance in Bangladesh and Pakistan^{5,48,49}. Funding for unproven treatments, especially where there are increasing prices due to shortages, can divert valuable resources away from treating other priority infectious diseases as well as non-communicable diseases (NCDs) such as coronary vascular disease (CVD) and diabetes, which are on the increase across countries^{5,50,51}. Instigating an evidence-based philosophy among all key stakeholder groups including physicians and pharmacists, starting in university and continuing, can help improve the situation in the future^{13,52}. We have seen this philosophy work in practice in Stockholm, Sweden, where there are high adherence rates among prescribing physicians to a list of just 200 medicines in ambulatory care (the 'Wise List') covering over 95% of the needs of patients. High adherence rates have been achieved through instigating robust evidence-based systems for reviewing medicines for incorporating into the list including strong conflict-of-interest statements. Alongside this, actively broadcasting the List through multiple channels including making a patient version available, physicians able to robustly question those compiling the list as well as continual monitoring of physician prescribing against the recommendations with feedback on a monthly basis^{53,54}. Robust evidence-based approaches have enhanced physician trust in the recommendations, which is reflected in high adherence rates⁵⁵. Some countries have also started fines for instigating companies and individuals broadcasting misinformation during the pandemic, providing direction to others¹³. Patient organisations can also play a role addressing misinformation regarding prevention and management of COVID-19 through social media and other approaches¹³, with evidence showing that patients do take on board key messages during the pandemic⁵⁶.

Inappropriate prescribing of antimicrobials will

also increase resistance rates alongside costs to governments, health authorities and patients, which is a key concern across all countries⁵⁷⁻⁵⁹. Community pharmacists and others can play a key role in reducing inappropriate prescribing and dispensing of antimicrobials, enhanced through educational input to address any information gaps in their knowledge^{57,60-62}. Patient education will also typically be needed to reduce requests for antimicrobials especially in countries with high levels of self-purchasing⁵⁷.

There are also concerns with the level of stigma associated with those who manage patients with COVID-19 along with those with the virus⁶³⁻⁶⁵. Alongside this, a potential increase in mental health disorders as a result of lockdown measures, fears about morbidity and mortality with COVID-19 as well as adverse reactions from potential treatments^{13,66}. During pandemics, community pharmacists and others can help with educational and other approaches including increased use of telemedicine to address any stigma and mental health issues associated with the virus^{67,68}. Community pharmacists can also help address other unintended consequences from the pandemic. These include concerns with reduced immunisation, patients unable to obtain their medicines for priority diseases including NCDs, as well as patients with NCDs not adhering to their medicines, alongside communicating with patients on ways to reduce the spread of the virus⁶⁹⁻⁷². Addressing concerns with availability and adherence to medicines is especially important in patients with NCDs such as CVD and diabetes during the pandemic as highlighted by the WHO and others^{73,74}. Encouragingly there has been increase in the utilisation of personal protective equipment (PPE) across countries to help prevent the spread of COVID-19; however this has resulted in shortages and associated price rises^{5,13,75}. Shortages are though being addressed through increasing local production in a number of countries, and this is likely to remain^{13,76}. However care is needed to address concerns with sub-standard or falsified medicines, which are likely to increase where there are medicine shortages^{13,77}. Initiatives such as the Lomé initiative, which places falsified and substandard medicines on the highest political agenda, alongside current

measures to strengthen the legal response to falsified medicines, are considerations for the future in pertinent developing countries⁷⁸.

In conclusion, COVID-19 has had, and continues to have, a devastating effect across countries. Its health impact can be minimised by rapid instigation of preventative measures. However, there needs to be plans in place to reduce the unintended consequences of lockdown measures, which can be significant. Governments and healthcare professionals also need to be proactive to reduce the spread of misinformation and any hype surrounding unproven treatments as

this can also be catastrophic for families especially in developing countries with high co-payment levels. Finally, the economic and health consequences of preventative strategies also need to be considered alongside the gains since their overall impact could be greater than the morbidity and mortality associated with COVID-19 in the first place. This is especially important for COVID-19 in countries with younger populations, and where an appreciable number of citizens rely on daily work for their survival. We will continue to monitor the unintended consequences across countries to provide future direction.

References:

1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. **2020**;323(13):1239-42
2. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med*. **2020**;382(13):1199-207
3. Anwar S, Nasrullah M, Hosen MJ. COVID-19 and Bangladesh: Challenges and How to Address Them. *Front Public Health*. **2020**;8:154. doi:10.3389/fpubh.2020.00154
4. WHO. Coronavirus disease (COVID-19) Situation Report – 182. **2020**. Available at URL: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200720-covid-19-sitrep-182.pdf?sfvrsn=60aabc5c_2
5. Haque M, Islam S, Iqbal S, Urmi UL, Kamal ZM, Shuvo SA et al. Availability and price changes of potential medicines and equipment for the prevention and treatment of COVID-19 among pharmacy and drug stores in Bangladesh; findings and implications. *Bangladesh Journal of Medical Science*. **2020**; Special Issue on Covid19: S36-S50 DOI:<https://doi.org/10.3329/bjms.v19i0.48106>
6. Haque M. Combating COVID-19: A Coordinated Efforts of Healthcare Providers and Policy Makers with Global Participation Are Needed to Achieve the Desired Goals. *Bangladesh Journal of Medical Science*. **2020**. Special Issue on Covid19: S1-05. DOI: <https://doi.org/10.3329/bjms.v19i0.47610>.
7. Chu DK, Akh EA, Duda S, Solo K, Yaacoub S, Schünemann HJ, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet*. **2020**:S0140-6736(20)31142-9. doi: 10.1016/S0140-6736(20)31142-9.
8. WHO. COVID-19 Strategic Preparedness and Response Plan - OPERATIONAL PLANNING GUIDELINES TO SUPPORT COUNTRY PREPAREDNESS AND RESPONSE. **2020**. Available at URL: <https://www.who.int/docs/default-source/coronaviruse/covid-19-sprp-unct-guidelines.pdf>.
9. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19. *N Engl J Med*. **2020**. doi: 10.1056/NEJMe2009758
10. Ng Y, Li Z, Chua YX, Chaw WL, Zhao Z, Er B, et al. Evaluation of the Effectiveness of Surveillance and Containment Measures for the First 100 Patients with COVID-19 in Singapore - January 2-February 29, 2020. *MMWR*. **2020**;69(11):307-11. doi: 10.15585/mmwr.mm6911e1
11. Tang KHD. Movement control as an effective measure against Covid-19 spread in Malaysia: an overview. *Zeitschrift Fur Gesundheitswissenschaften*. **2020**:1-4. doi: 10.1007/s10389-020-01316-w
12. Nussbaumer-Streit B, Mayr V, Dobrescu AI, Chapman

- A, Persad E, Klerings I, et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. *The Cochrane database of systematic reviews*. 2020;4:Cd013574. doi: 10.1002/14651858.CD013574
13. Ogunleye OO, Basu D, Mueller D, Sneddon J, Seaton RA, Yinka-Ogunleye AF et al. RESPONSE TO THE NOVEL CORONA VIRUS (COVID-19) PANDEMIC ACROSS AFRICA: SUCCESSES, CHALLENGES AND IMPLICATIONS FOR THE FUTURE. *Frontiers in Pharmacology*. 2020 (Accepted for publication - doi: 10.3389/fphar.2020.0120
 14. DW. Coronavirus: Is Pakistan taking COVID-19 too lightly? 2020. Available at URL: <https://www.dw.com/en/coronavirus-is-pakistan-taking-covid-19-too-lightly/a-52824403>.
 15. Thai PQ, Rabaa MA, Luong DH, Tan DQ, Quang TD, Quach H-L et al. The first 100 days of SARS-CoV-2 control in Vietnam. 2020. MedRxiv preprint doi: <https://doi.org/10.1101/2020.05.12.20099242.t>.
 16. Jones A. Coronavirus: How 'overreaction' made Vietnam a virus success. 2020. Available at URL: <https://www.bbc.co.uk/news/world-asia-52628283>.
 17. Ministry of Health, VietNam. Hướng dẫn chẩn đoán và điều trị viêm đường hô hấp cấp do SARS-CoV-2 (COVID-19) phiên bản lần thứ 3. 2020. Available at URL: <https://kcb.vn/huong-dan-chan-doan-va-dieu-tri-viem-duong-ho-hap-cap-do-sar-cov-2-covid-19-phi-ban-lan-thu-3.html>.
 18. Sonwalkar P. Covid-19: Indians, non-whites in UK more at risk of death. 2020. Available at URL: <https://www.hindustantimes.com/indians-abroad/covid-19-indians-non-whites-in-uk-more-at-risk-of-death/story-aDtiNXMxE1xJJaPwSX9t4O.html>.
 19. Public Health England. Disparities in the risk and outcomes of COVID-19. 2020. Available at URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/892085/disparities_review.pdf.
 20. Khunti K, Singh AK, Pareek M, Hanif W. Is ethnicity linked to incidence or outcomes of covid-19? *BMJ*. 2020;369:m1548. doi: 10.1136/bmj.m1548
 21. Kirby T. Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities. *The Lancet Respiratory medicine*. 2020;8(6):547-8. doi: 10.1016/S2213-2600(20)30228-9
 22. El-Khatib Z, Jacobs GB, Ikomey GM, Neogi U. The disproportionate effect of COVID-19 mortality on ethnic minorities: Genetics or health inequalities? *EClinicalMedicine*. 2020;23:100430. doi: 10.1016/j.eclinm.2020.100430
 23. Jan H, Faisal S, Khan A, Khan S, Usman H, Liaqat R, et al. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. *Discoveries*. 2020;8(2):e108. doi: 10.15190/d.2020.5
 24. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. *Jama*. 2020. doi: 10.1001/jama.2020.6019
 25. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. *N Engl J Med*. 2020doi: 10.1056/NEJMoa2007764
 26. ECDC. ECDC - Vaccines and treatment of COVID-19. 2020. Available at URL: <https://www.ecdc.europa.eu/en/covid-19/latest-evidence/vaccines-and-treatment>.
 27. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. medRxiv. 2020. doi: <https://doi.org/10.1101/2020.06.22.20137273>
 28. Gallagher F. Tracking hydroxychloroquine misinformation: How an unproven COVID-19 treatment ended up being endorsed by Trump. ABC News. 2020. Available at URL: <https://abcnews.go.com/Health/tracking-hydroxychloroquine-misinformation-unproven-covid-19-treatment-ended/story?id=70074235>.
 29. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *International journal of antimicrobial agents*. 2020:105949. doi: 10.1016/j.ijantimicag.2020.105949
 30. Littlejohn E. Hydroxychloroquine use in the COVID-19 patient. *Cleveland Clinic journal of medicine*. 2020. doi: 10.3949/ccjm.87a.ccc011
 31. International Society of Antimicrobial Chemotherapy. Official Statement from International Society of Antimicrobial Chemotherapy (ISAC) - Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial (Gautret P et al. PMID 32205204). 2020. Available at URL: <https://www.isac.world/news-and-publications/official-isac-statement>.
 32. Abena PM, Decloedt EH, Bottieau E, Suleman F, Adejumo P, Sam-Agudu NA, et al. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings. *Am J Trop Med Hyg*. 2020;102(6):1184-8. doi: 10.4269/ajtmh.20-0290
 33. Nga L, Phuong L, Anh P. Hanoi man OD's on rumored malaria drug cure for Covid-19. 2020. Available at URL: <https://e.vnexpress.net/news/news/hanoi-man-od-s-on-rumored-malaria-drug-cure-for-covid-19-4073488.html>.
 34. Busari S, Adebayo B. Nigeria records chloroquine poisoning after Trump endorses it for coronavirus treatment. 2020. Available at URL: <https://www.cnnphilippines.com/world/2020/3/23/nigeria-chloroquine-poisoning-trump-coronavirus.html>.
 35. Tilangi P, Desai D, Khan A, Soneja M. Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach. *The Lancet Infectious diseases*. 2020. doi: 10.1016/S1473-3099(20)30430-8
 36. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA,

- Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *N Engl J Med.* **2020**. doi: 10.1056/NEJMoa2016638
37. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med.* **2020**;382(25):2411-2418. doi:10.1056/NEJMoa2012410
 38. Borba MGS, Almeida Val FF, Sampaio VS, Alexandre MAA, Melo GC, Brito M et al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIB clinical trial (CloroCovid-19 Study). **2020**. MedRxiv preprint doi: <https://doi.org/10.1101/2020.04.07.20056424>
 39. Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. *BMJ.* **2020**;369:m1432. doi:10.1136/bmj.m1432
 40. RECOVERY Trial. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. **2020**. Available at URL: <https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19>.
 41. WHO. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. **2020**. Available at URL: <https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19>.
 42. NIH. NIH halts clinical trial of hydroxychloroquine. **2020**. Available at URL: <https://www.nhlbi.nih.gov/news/2020/nih-halts-clinical-trial-hydroxychloroquine>.
 43. European Medicine Agency. COVID-19: reminder of risk of serious side effects with chloroquine and hydroxychloroquine. **2020**. Available at URL: <https://www.ema.europa.eu/en/news/covid-19-reminder-risk-serious-side-effects-chloroquine-hydroxychloroquine>.
 44. Ying TP. Dr Noor Hisham: Malaysia drops use of hydroxychloroquine for Covid-19. **2020**. Available at URL: <https://www.nst.com.my/news/nation/2020/06/602538/dr-noor-hisham-malaysia-drops-use-hydroxychloroquine-covid-19>.
 45. SAHPRA. SAHPRA cautions against medicine stockpiling including Chloroquine containing products. **2020**. Available at URL: http://www.sahpra.org.za/wp-content/uploads/2020/03/SAHPRA-communicate_Chloroquine-Stockpiling_23032020.pdf.
 46. Chatterjee P, Anand T, Singh KJ, Rasaily R, Singh R, Das S, et al. Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19. *Indian J Med Res.* **2020**;151(5):459-67. doi: 10.4103/ijmr.IJMR_2234_20
 47. Rathi S, Ish P, Kalantri A, Kalantri S. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. *The Lancet Infectious diseases.* **2020**. doi: 10.1016/S1473-3099(20)30313-3
 48. Hsu J, Flores G, Evans D, Mills A, Hanson K. Measuring financial protection against catastrophic health expenditures: methodological challenges for global monitoring. *International journal for equity in health.* **2018**;17(1):69. doi: 10.1186/s12939-018-0749-5
 49. Pakistan Today. Pakistan's healthcare system. **2020**. <https://www.pakistantoday.com.pk/2020/01/08/pakistans-healthcare-system/>.
 50. Godman B, Basu D, Pillay Y, Mwita JC, Rwegerera GM, Anand Paramadhas BD, et al. Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future. *Front Pharmacol.* **2020**;11:108. doi:10.3389/fphar.2020.00108.
 51. Gheorghe A, Griffiths U, Murphy A, Legido-Quigley H, Lamptey P, Perel P. The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review. *BMC public health.* **2018**;18(1):975. doi: 10.1186/s12889-018-5806-x
 52. COUNCILFORINTERNATIONALORGANIZATIONS OF MEDICAL SCIENCES. Medicines assessment during public health emergencies needs good science, best practices and proper communication. **2020**. Available at URL: https://cioms.ch/wp-content/uploads/2020/06/CIOMS_WGXII_Statement.pdf.
 53. Gustafsson LL, Wettermark B, Godman B, Andersen-Karlsson E, Bergman U, Hasselstrom J, et al. The 'wise list' - a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. *Basic & clinical pharmacology & toxicology.* **2011**;108(4):224-33. doi: 10.1111/j.1742-7843.2011.00682.x
 54. Bjorkhem-Bergman L, Andersen-Karlsson E, Laing R, Diogene E, Melien O, Jirlow M, et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. *European journal of clinical pharmacology.* **2013**;69 Suppl 1:73-8. doi: 10.1007/s00228-013-1497-5
 55. Eriksen J, Gustafsson LL, Ateva K, Bastholm-Rahmner P, Ovesjo ML, Jirlow M, et al. High adherence to the 'Wise List' treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines. *BMJ open.* **2017**;7(4):e014345. doi: 10.1136/bmjopen-2016-014345
 56. Hayat K, Rosenthal M, Xu S, Arshed M, Li P, Zhai P, et al. View of Pakistani Residents toward Coronavirus Disease (COVID-19) during a Rapid Outbreak: A Rapid Online Survey. *Int J Environ Res Public Health.* **2020**;17(10). doi: 10.3390/ijerph17103347

57. Godman B, Haque M, McKimm J, Abu Bakar M, Sneddon J, Wale J, et al. Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future. *Current medical research and opinion*. **2020**;36(2):301-27. doi: 10.1080/03007995.2019.1700947
58. World Health Organisation. Antimicrobial resistance. **2018**. Available at URL: <http://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>.
59. Hofer U. The cost of antimicrobial resistance. *Nature reviews Microbiology*. **2019**;17(1):3. doi: 10.1038/s41579-018-0125-x
60. Mukokinya M, Opanga S, Oluka M, Godman B. Dispensing of antimicrobials in Kenya: A cross-sectional pilot study and its implications. *Journal of Research in Pharmacy Practice*. **2018**;7(2):77-82. doi: 10.4103/jrpp.JRPP_17_88
61. Hoxha I, Malaj A, Kraja B, Bino S, Oluka M, Markovic-Pekovic V, et al. Are pharmacists' good knowledge and awareness on antibiotics taken for granted? The situation in Albania and future implications across countries. *Journal of global antimicrobial resistance*. **2018**;13:240-5. doi: 10.1016/j.jgar.2018.01.019
62. Saleem Z, Hassali MA, Hashmi FK, Godman B, Saleem F. Antimicrobial dispensing practices and determinants of antimicrobial resistance: a qualitative study among community pharmacists in Pakistan. *Family medicine and community health*. **2019**;7(3):e000138. doi: 10.1136/fmch-2019-000138
63. Kamal RS. Fear, hatred and stigmatization grip Bangladesh amid Covid-19 outbreak. **2020**. Available at URL: <https://tbsnews.net/thoughts/fear-hatred-and-stigmatization-grip-bangladesh-amid-covid-19-outbreak-61129>.
64. Shammi M, Bodrud-Doza M, Towfiqul Islam ARM, Rahman MM. COVID-19 pandemic, socioeconomic crisis and human stress in resource-limited settings: A case from Bangladesh. *Heliyon*. **2020**;6(5):e04063-e. doi: 10.1016/j.heliyon.2020.e04063
65. IFRC, UNICEF and WHO. Social Stigma associated with COVID-19. **2020**. Available at URL: <https://reliefweb.int/sites/reliefweb.int/files/resources/covid19-stigma-guide.pdf>.
66. González-Sanguino C, Ausín B, Castellanos M, Saiz J, López-Gómez A, Ugidos C, et al. Mental health consequences during the initial stage of the 2020 Coronavirus pandemic (COVID-19) in Spain. *Brain, behavior, and immunity*. **2020**. doi: 10.1016/j.bbi.2020.05.040
67. Webster P. Virtual health care in the era of COVID-19. *Lancet*. **2020**;395(10231):1180-1. doi: 10.1016/S0140-6736(20)30818-7
68. LinksCommunity. Leveraging Technology to Improve Health Care During the COVID-19 Pandemic and Beyond. **2020**. Available at URL: https://linkscommunity.org/assets/PDFs/cov039_telemedicine_v3_14may2020.pdf.
69. Cash R, Patel V. The art of medicine - Has COVID-19 subverted global health? *Lancet*. **2020**; 395: 1687-8. doi: 10.1016/S0140-6736(20)31089-8
70. Hedima EW, Adeyemi MS, Ikunaiye NY. Community Pharmacists: On the frontline of health service against COVID-19 in LMICs. *Research in social & administrative pharmacy*. **2020**. doi: 10.1016/j.sapharm.2020.04.013
71. Cadogan CA, Hughes CM. On the frontline against COVID-19: Community pharmacists' contribution during a public health crisis. *Research in social & administrative pharmacy*. **2020**. doi: 10.1016/j.sapharm.2020.03.015
72. San-Juan-Rodriguez A, Newman TV, Hernandez I, Swart ECS, Klein-Fedyshin M, Shrank WH, et al. Impact of community pharmacist-provided preventive services on clinical, utilization, and economic outcomes: An umbrella review. *Prev Med*. **2018**;115:145-55. doi: 10.1016/j.ypmed.2018.08.029
73. Kluge HHP, Wickramasinghe K, Rippin HL, Mendes R, Peters DH, Kontsevaya A, et al. Prevention and control of non-communicable diseases in the COVID-19 response. *Lancet*. **2020**;395(10238):1678-80 doi: 10.1016/S0140-6736(20)31067-9.
74. Basu S. Non-communicable disease management in vulnerable patients during Covid-19. *Indian journal of medical ethics*. **2020**;V(2):103-5 doi: 10.20529/IJME.2020.041
75. Dabanga. OCHA Sudan: Medical supplies may be affected by Covid-19 measures. **2020**. Available at URL: <https://www.dabangasudan.org/en/relief-news/article/ocha-sudan-medical-supplies-may-be-affected-by-covid-19-measures>.
76. Thuy N. Vietnam pushes for medicine self-sufficiency post Covid-19: Fitch Solutions. 3 June **2020**. Available at URL: <http://hanoitimes.vn/vietnam-pushes-for-medicine-self-sufficiency-post-covid-19-fitch-solutions-312399.html>.
77. World Health Organisation. Medical Product Alert N°4/2020 - Falsified chloroquine products circulating in the WHO region of Africa. **2020**. Available at URL: https://www.who.int/docs/default-source/essential-medicines/drug-alerts20/drug-alert-4/n-4-2020-falsified-chloroquine-en.pdf?sfvrsn=c4354802_6.
78. WHO. Launch of the Lomé Initiative. **2020**. Available at URL: <https://www.who.int/dg/speeches/detail/launch-of-the-lom%C3%A9-initiative>.